Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
RESEARCH TOOLSreports
SPRY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.18 - $18.51
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.30M
Market Cap
$1.14B
Enterprise Value$1.20B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Mar 20, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding97,185,480
10 Day Avg. Volume1,023,207
30 Day Avg. Volume1,295,434
Standard Deviation0.21
R-Squared0.05
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)445.43
Price to Cash Flow (P/CF)-19.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-27.96K
Enterprise Value/Ebitda-19.89
Forecast
1Y Price Target
$34.00Price Target Upside183.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityWith a year-end cash position of approximately $314 million, the company expects to be well-capitalized to support operations for at least three years, allowing flexibility to increase marketing activities and expand the sales force.
US LaunchMultiple tailwinds such as accelerating patient awareness, favorable payer coverage, and broader physician adoption are expected to benefit neffy’s US launch, which should bode well for SPRY stock.
Bears Say
Sales ForecastsThe 4Q24 and FY25 neffy sales forecasts have been adjusted downward, reflecting a slower run-rate than previously expected.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $7.18 and its highest was $18.51 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $1.14B.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Mar 20, 2025 which is in 27 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.058.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.14.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 97,185,480 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -15.232%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
---
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (183.33% Upside)
$34.00 (183.33% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.36%
12-Months-Change
Fundamentals
Return on Equity
-22.41%
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
---
SPRY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including the successful approval and initial launch of Neffy, a strategic partnership with ALK, and a strong financial position. While there were minor challenges with inventory stocking and cash price redemption, the overall sentiment is positive due to the strong early sales and enthusiastic reception by healthcare providers and patients.Read More>---
SPRY Stock 12 Month Forecast
Average Price Target
$34.00
▲(183.33% Upside)
Technical Analysis
Best Analysts Covering SPRY
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+103.45%
initiated a buy rating 12 days ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +103.45% per trade.
---